Sopharma Group has acquired two pharmaceutical products in Poland
Sopharma Group has acquired Coffepirine and Kopiryna, two highly recognized medicines to treat headache. The acquisition will further expand the market presence of Sopharma Group in the Polish market and support the promising potential of the two pharmaceutical drugs.
Sopharma Group is a leading producer and distributor of healthcare products in the CEE, with a vertically integrated business model running through the whole value chain, with its own R&D, manufacturing and wholesale and retail distribution. The company is present in 33 countries and has a portfolio consisting of more than 200 products.
Coffepirine and Kopiryna are OTC analgesics with APIs based on a combination of acetylsalicylic acid and caffeine, which have helped the Polish public to treat headaches for decades. The drugs are developed and manufactured by Medicofarma, a well-known Polish pharmaceuticals company.
Medicofarma is a pharmaceutical manufacturing company focusing on contract manufacturing of pharmaceuticals, medicinal products and dietary supplements. The company has a modern factory equipped with state-of-the-art technology and meets all GMP requirements.
Oaklins’ team in Bulgaria acted as buy-side advisor to Sopharma Group, leading the transaction process, deal structuring and negotiations, and assisting throughout the acquisition process.
Talk to the deal team
Related deals
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Learn moreEuroHospital Varna has been acquired by Intermedica Group
EuroHospital Varna has been acquired by Intermedica Group, allowing the business to continue to grow and deliver high-quality healthcare services to its patients. Through the transaction, Intermedica Group expands its healthcare presence and intends to build a new model of integrated personalized care focused on preventive, holistic and digital medicine.
Learn moreOlyos Group has acquired a controlling stake in NewScience
Olyos Group has acquired a controlling stake in NewScience from its founders through a transaction structured in two stages, with the strategic objective of ultimately acquiring 100% of the company. The transaction forms part of NewScience’s international growth strategy and a gradual cash-out process for the founder, who intends to complete a full exit. Olyos intends to retain the management team through a put and call option mechanism and an earn-out linked to NewScience’s 2025 EBITDA.
Learn more